Proteins.1, a Finnish deep-tech startup, has launched with a mission to revolutionize early disease detection through single-molecule protein amplification. The VTT-originated company recently secured €4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures. This investment will fuel the commercialization of its technology, which aims to identify diseases long before they become clinically visible.
A New Frontier in Diagnostics
For decades, diagnostics has lacked a protein equivalent to the Polymerase Chain Reaction (PCR) used for genetic material. Proteins often serve as the earliest warning signals for conditions like cancer, neurodegeneration, and cardiovascular disease. Proteins.1 aims to fill this critical gap, shifting the paradigm from reactive treatment to proactive, preventative healthcare.
Pioneering Physics-Based Amplification
The company's patented technology introduces a novel physics-based approach to protein detection, promising up to 1,000 times greater sensitivity than current standards. Instead of enzymatic reactions, it uses a magnetic cycling mechanism to repeatedly read a single protein molecule, amplifying its signal without background noise. This solid-state, enzyme-free method allows for high multiplexing from just a few drops of blood.
Strategic Funding and Market Entry
The significant pre-seed funding will enable Proteins.1 to advance its platform, initially targeting research-use-only applications in oncology, neurology, and immunology. CEO Prateek Singh stated that the mission is to make the body's early warning signals measurable and actionable years earlier than is possible today. The company will later progress toward regulated clinical diagnostics to maximize its impact on patient care.
Investors have expressed strong confidence in the company's potential to redefine the industry. Jyri Engeström of Lifeline Ventures praised the team's combination of world-class research and medtech business experience. Rene Kromhof from Cloudberry VC highlighted the fundamentally new sensing approach that dramatically improves sensitivity and how early disease can be caught.
Leadership and Future Outlook
The founding team brings extensive experience in microfluidics, photonics, and regulated medical devices to the venture. CEO Prateek Singh is the inventor of the core technology, while COO Harri Hallila has successfully built and exited a medical device company. Proteins.1 plans to expand its engineering and product development team in Finland during 2026-2027.
Proteins.1 is poised to make a significant impact on the €100 billion global diagnostics market with its breakthrough technology. By enabling the detection of disease at the molecular stage, the company offers the potential to transform treatment possibilities and improve patient outcomes. This innovation could usher in a new era of preventative medicine, extending healthy lifespans worldwide.